JP2024028756A5 - - Google Patents

Download PDF

Info

Publication number
JP2024028756A5
JP2024028756A5 JP2023199561A JP2023199561A JP2024028756A5 JP 2024028756 A5 JP2024028756 A5 JP 2024028756A5 JP 2023199561 A JP2023199561 A JP 2023199561A JP 2023199561 A JP2023199561 A JP 2023199561A JP 2024028756 A5 JP2024028756 A5 JP 2024028756A5
Authority
JP
Japan
Prior art keywords
recombinant protein
domain
dosage unit
antibody
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023199561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024028756A (ja
Filing date
Publication date
Priority claimed from PCT/EP2021/059570 external-priority patent/WO2021209452A1/en
Application filed filed Critical
Publication of JP2024028756A publication Critical patent/JP2024028756A/ja
Publication of JP2024028756A5 publication Critical patent/JP2024028756A5/ja
Pending legal-status Critical Current

Links

JP2023199561A 2020-04-14 2023-11-27 インターロイキン-12とフィブロネクチンのエクストラドメインbに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤 Pending JP2024028756A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20169469.2 2020-04-14
EP20169469 2020-04-14
PCT/EP2021/059570 WO2021209452A1 (en) 2020-04-14 2021-04-13 Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain b of fibronectin
JP2022561419A JP7438396B2 (ja) 2020-04-14 2021-04-13 インターロイキン-12とフィブロネクチンのエクストラドメインbに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022561419A Division JP7438396B2 (ja) 2020-04-14 2021-04-13 インターロイキン-12とフィブロネクチンのエクストラドメインbに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤

Publications (2)

Publication Number Publication Date
JP2024028756A JP2024028756A (ja) 2024-03-05
JP2024028756A5 true JP2024028756A5 (cg-RX-API-DMAC10.html) 2024-04-18

Family

ID=70289595

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022561419A Active JP7438396B2 (ja) 2020-04-14 2021-04-13 インターロイキン-12とフィブロネクチンのエクストラドメインbに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤
JP2023199561A Pending JP2024028756A (ja) 2020-04-14 2023-11-27 インターロイキン-12とフィブロネクチンのエクストラドメインbに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022561419A Active JP7438396B2 (ja) 2020-04-14 2021-04-13 インターロイキン-12とフィブロネクチンのエクストラドメインbに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤

Country Status (5)

Country Link
US (1) US20230312726A1 (cg-RX-API-DMAC10.html)
EP (1) EP4135751B1 (cg-RX-API-DMAC10.html)
JP (2) JP7438396B2 (cg-RX-API-DMAC10.html)
AU (1) AU2021257594B2 (cg-RX-API-DMAC10.html)
WO (1) WO2021209452A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250073239A1 (en) * 2022-01-04 2025-03-06 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
EP4780495A1 (en) 2023-09-19 2026-07-29 Philochem AG Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013875A (es) * 2005-05-11 2008-01-28 Philogen Spa Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12.
JP2009536170A (ja) 2006-05-08 2009-10-08 フィロジェン・エッセペア 治療用の抗体標的指向サイトカイン
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
US20210137919A1 (en) 2018-02-07 2021-05-13 Smawa Gmbh Pharmaceutical formulations, method for producing a pharmaceutical formulation, and medicament comprising same
TWI844524B (zh) 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
CA3097058A1 (en) 2018-04-16 2019-10-24 Merck Patent Gmbh Additives for protein formulations to improve thermal stability

Similar Documents

Publication Publication Date Title
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP6283665B2 (ja) Gd2陽性癌を治療するための方法
EP3076972B1 (en) Cancer treatment with combination of plinabulin and taxane
JP6241932B2 (ja) 腫瘍性疾患のための治療
JP2003504413A (ja) 抗腫瘍物質を含む組み合わせ調製物
JP2021534094A5 (cg-RX-API-DMAC10.html)
KR20220157515A (ko) Liv1-adc와 화학요법제를 사용한 병용 요법
TWI817958B (zh) 用於治療肝癌之組合物及方法
US20200254037A1 (en) Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
Razak et al. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: ARA Razak et al.
WO2025103377A1 (zh) 抗b7h3抗体-药物偶联物治疗癌症的方法
JP2004518717A (ja) 標的化された抗腫瘍剤送達系
CN112584861A (zh) 使用组合疗法治疗癌症的方法
JP7438396B2 (ja) インターロイキン-12とフィブロネクチンのエクストラドメインbに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤
JP2024511977A5 (cg-RX-API-DMAC10.html)
JP2023549698A (ja) がんの治療のためのナノ粒子の組成物
Fattoruso et al. Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer
US20250019441A1 (en) Treatment of cancer with anti-ilt2 antibodies
JP2022531894A5 (cg-RX-API-DMAC10.html)
Muro et al. P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancers
HK40122430A (en) Method for treating cancer with anti-b7h3 antibody-drug conjugate
WO2025245200A1 (en) Ponsegromab for use in treating cachexia in cancer patients
WO2025185682A1 (zh) 含有抗egfr抗体或其片段的联合用药物
WO2026046060A1 (zh) 抗b7h3抗体药物偶联物用于治疗癌症的方法
WO2025159982A1 (en) Treatment of non-small cell lung cancer using sacituzumab govitecan